CXCR2/CD182/IL8RB Full-Length Nanodisc Proteins, ECDs and Flow Antibodies

C-X-C Chemokine Receptor Type 2 (CXCR2), also known as CD182 or IL8RB, is a class A G protein-coupled chemokine receptor with a seven-transmembrane architecture. It recognizes multiple ELR-positive CXC chemokines, including CXCL1, CXCL2, CXCL5, and CXCL8, and signals primarily through Gi proteins to regulate calcium mobilization, chemotaxis, and cell migration. CXCR2 is highly expressed on neutrophils and is a key regulator of their recruitment from blood into inflamed tissues. It is therefore widely studied in inflammatory, infectious, and pulmonary diseases. Within tumors, CXCR2 signaling can also promote recruitment of neutrophils and myeloid-derived suppressor cells, influence angiogenesis, and reshape the immune microenvironment. Because CXCR2 is a GPCR with conformation-dependent extracellular epitopes, native membrane presentation is especially valuable for functional antibody discovery.

DIMA BIOTECH provides full-length human CXCR2 in Synthetic Nanodisc formats, including conventional, Strep-tagged, and biotinylated versions for native-conformation antibody screening, SPR/BLI, binding characterization, and specificity assessment. Human, mouse, and cynomolgus CXCR2 ECD/N-terminal proteins support ELISA, epitope studies, and cross-species evaluation. A flow cytometry-validated chimeric monoclonal antibody is available in unconjugated, PE-conjugated, and biotinylated formats for cell-surface detection and candidate benchmarking. In addition, to accelerate the development of CXCR2 biotherapy, DIMA BIOTECH has also prepared a CXCR2 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple CXCR2 IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.